노인 환자에서 Vancomycin 사용과 관련한 신독성의 위험인자 연구
Risk Factors for Vancomycin-Associated Nephrotoxicity in Elderly Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Infection is very common in the elderly, so there is a high prevalence of antibiotics use among this population. Especially, due to the emergence of resistant bacteria, the use of vancomycin is growing. The purpose of this study was to evaluate risk factors associated with vancomycin-induced nephrotoxicity in elderly patients. Methods: The subjects of this study were patients over 18 years old who received intravenous vancomycin in a general hospital located in Gangneung-si, Korea between August 1, 2013 and July 31, 2015. Data collection regarding vancomycin use and baseline characteristics was conducted using computerized hospital database. Logistic regression analysis was used to identify risk factors associated with vancomycin-induced nephrotoxicity. Results: A total of 290 patients were finally included, and 191(66%) out of these patients were age 65 or older. The incidence of vancomycin-induced nephrotoxicity was 11.0%, 12.6%, and 7.0% in the all adult patients, the elderly patients, and the non-elderly patients, respectively. There were significant differences in comorbidities between patients with nephrotoxicity and patients without nephrotoxicity in the all adult patients, and there were significant differences in vancomycin duration, comorbidities, and number of nephrotoxic agents between patients with nephrotoxicity and patients without nephrotoxicity in the elderly patients. However, according to the logistic regression analysis, there was no significant risk factor that increases the incidence ofvancomycin-induced nephrotoxicity in all three age groups. Conclusion: There were no differences in risk factors that increase the incidence of vancomycin-induced nephrotoxicity between all adult patients, elderly patients, and non-elderly patients. Further studies with larger sample sizes to identify risk factors associated with vancomycin-induced nephrotoxicity in the elderly to improve the outcome of pharmacotherapy are required.
Abstract
Objective: Infection is very common in the elderly, so there is a high prevalence of antibiotics use among this population. Especially, due to the emergence of resistant bacteria, the use of vancomycin is growing. The purpose of this study was to evaluate risk factors associated with vancomycin-induced nephrotoxicity in elderly patients. Methods: The subjects of this study were patients over 18 years old who received intravenous vancomycin in a general hospital located in Gangneung-si, Korea between August 1, 2013 and July 31, 2015. Data collection regarding vancomycin use and baseline characteristics was conducted using computerized hospital database. Logistic regression analysis was used to identify risk factors associated with vancomycin-induced nephrotoxicity. Results: A total of 290 patients were finally included, and 191(66%) out of these patients were age 65 or older. The incidence of vancomycin-induced nephrotoxicity was 11.0%, 12.6%, and 7.0% in the all adult patients, the elderly patients, and the non-elderly patients, respectively. There were significant differences in comorbidities between patients with nephrotoxicity and patients without nephrotoxicity in the all adult patients, and there were significant differences in vancomycin duration, comorbidities, and number of nephrotoxic agents between patients with nephrotoxicity and patients without nephrotoxicity in the elderly patients. However, according to the logistic regression analysis, there was no significant risk factor that increases the incidence ofvancomycin-induced nephrotoxicity in all three age groups. Conclusion: There were no differences in risk factors that increase the incidence of vancomycin-induced nephrotoxicity between all adult patients, elderly patients, and non-elderly patients. Further studies with larger sample sizes to identify risk factors associated with vancomycin-induced nephrotoxicity in the elderly to improve the outcome of pharmacotherapy are required.
참고문헌 (41)
- Wang H, "Age-specific and sexspecific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380(9859), pp.2071~2094 (2013)
- Yoshikawa TT, "Infections in the aging population", J Am Geriatr Soc, 33(7), pp.496~503 (1985)
- Beeson P, "Alleged susceptibility of the elderly to infection", Yale J Biol Med, 58(2), pp.71~ (1985)
- Jackson MM, "Infections end infection risk in residents of longterm care facilities: A review of the literature, 1970-1994", Am J Infect Control, 13(2), pp.63~77 (1985)
- Berg RL, "The second fifty years: Promoting health and preventing disability" (1990), National Academy Press
- Walsh C., "Antibiotics" (2003), American Society of Microbiology
- Reynolds PE, "Structure, biochemistry and mechanism of action of glycopeptide antibiotics", Eur J Clin Microbiol Infect Dis, 8(11), pp.943~950 (1989)
- Beard Jr EL, "The American Society of Health System Pharmacists", JONAS Healthc Law Ethics Regul, 3(3), pp.78~79 (2001)
- Liu C, "Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children", Clin Infect Dis, 52(3), pp.e18~e55 (2011)
- 김도균, "Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) Data From 2013 to 2015", Annals of Laboratory Medicine, 37(3), pp.231~239 (2017), 대한진단검사의학회
- Patel R, "Vancomycin-resistant enterococcal bacteremia pharmacotherapy", Ann Pharmacother, 49(1), pp.69~85 (2015)
- Lodise TP, "Larger vancomycin doses(at least four grams per day)are associated with an increased incidence of nephrotoxicity", Antimicrob Agents Chemother, 52(4), pp.1330~1336 (2008)
- Lodise TP, "Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients", Clin Infect Dis, 49(4), pp.507~514 (2009)
- Hidayat LK, "High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections : efficacy and toxicity", Arch Intern Med, 166(19), pp.2138~2144 (2006)
- Fangtang JT, "Vancomycin: predictive risk factors for nephrotoxicity and implication for monitoring" (1996)
- Minejima E, "Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients", Antimicrob Agents Chemother, 55(7), pp.3278~3283 (2011)
- Elyasi S, "Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review", Eur J Clin Pharmacol, 68(9), pp.1243~1255 (2012)
- Kirst HA, "Historical yearly usage of vancomycin", Antimicrob Agents Chemother, 42(5), pp.1303~1304 (1998)
- Horey A, "The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population : a retrospective analysis", Ann Pharmacother, 46(11), pp.1477~1483 (2012)
- Meaney CJ, "Vancomycin-Associated Nephrotoxicity in Adult Medicine Patients: Incidence, Outcomes, and Risk Factors", Pharmacotherapy, 34(7), pp.653~661 (2014)
- Cano EL, "Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia : retrospective analysis of the IMPACT-HAP Database", Clin Ther, 34(1), pp.149~157 (2012)
- Perazella MA, "Drug-induced nephropathy : an update", Expert Opin Drug Saf, 4(4), pp.689~706 (2005)
- Nash K, "Hospital-acquired renal insufficiency", Am J Kidney Dis, 39(5), pp.930~936 (2002)
- Toyoguchi T, "Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits", Antimicrob Agents Chemother, 41(9), pp.1985~1990 (1987)
- Nishino Y, "Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycininduced nephrotoxicity in rats", Free Radic Res, 37(4), pp.373~379 (2003)
- Dieterich C, "Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates", Toxicol Sci, 107(1), pp.258~269 (2009)
- Fanos V, "Renal transport of antibiotics and nephrotoxicity : a review", J Chemother, 13(5), pp.461~472 (2001)
- Carreno JJ, "Comparative incidence of nephrotoxicity by age group among adult patients receiving vancomycin", Infect Dis Ther, 2(2), pp.201~208 (2013)
- Vance-Bryan K, "A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient", J Antimicrob Chemother, 33(4), pp.811~821 (1994)
- Hidayat LK, "High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections : efficacy and toxicity", Arch Intern Med, 166(19), pp.2138~2144 (2006)
- Farber BF, "Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981", Antimicrob Agents Chemother, 23(1), pp.138~141 (1983)
- Perazella MA, "Renal vulnerability to drug toxicity", Clin J Am Soc Nephrol, 4(7), pp.1275~1283 (2009)
- Humes HD, "Aminoglycoside nephrotoxicity", Kidney Int, 33(4), pp.900~911 (1998)
- Kobori H, "The intrarenal renin-angiotensin system : from physiology to the pathobiology of hypertension and kidney disease", Pharmacol Rev, 59(3), pp.251~287 (2007)
- Cupples WA, "Assessment of renal autoregulation", Am J Physiol Renal Physiol, 292(4), pp.F1105~F23 (2007)
- Bosso JA, "Relationship between vancomycin trough concentrations and nephrotoxicity : a prospective multicenter trial", Antimicrob Agents Chemother, 55(12), pp.5475~5479 (2011)
- Rostas SE, "High-dose intravenous vancomycin therapy and the risk of nephrotoxicity", Clin Ther, 36(7), pp.1098~1101 (2014)
- Han HK, "Trough concentration over 12.1 mg", L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring, 2014, pp.36(5), 606~611
- Rahman M, "Acute kidney injury : a guide to diagnosis and management", Am Fam Physician, 86(7), pp.631~639 (2012)
- Van Hal S, "Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter", Antimicrob Agents Chemother, 57(2), pp.734~744 (2013)
- Mangoni AA, "Age-related changes in pharmacokinetics and pharmacodynamics : basic principles and practical applications", Br J Clin Pharmacol, 57(1), pp.6~14 (2004)